The UT Southwestern Medical Center at Coppell is now open and offering services close to communities in Coppell, Valley Ranch, Carrollton, and surrounding areas. Services include primary and preventative care, an onsite phlebotomy station, immunization for adults and for children, women’s health services, and chronic illness management. The center is located at Cypress Waters, a mixed-use community, at 2999 Olympus Blvd, Coppell, Texas, 75019.
Medical City Frisco is the first hospital in Texas and the fifth in the nation to use the world’s first artificial intelligence-driven, augmented reality system for spine surgery. The software is designed to achieve better surgical outcomes and to reduce surgical complications. Surgeons can generate a patient-specific 3D model of the patient’s anatomy, which is then used to guide the development of a personalized and specific surgical plan. This technology may result in less tissue damage and shorter surgery times.
Forty-five new physician residents will begin training at four Texas Health hospitals in July. The new physicians learned they secured a position in Texas Health Resources GME programs on Match Day 2023. The new residents will begin training at four campuses- Texas Health Presbyterian Hospital Dallas, Texas Health Harris Methodist Hospital Fort Worth, and a program with clinical rotations at Texas Health Presbyterian Hospital Denton and Texas Health Harris Methodist Hospital Hurst-Euless-Bedford.
UT Southwestern Medical Center will lead a national multi-center clinical trail to test a treatment strategy for pediatric cancer patients with solid tumors. The trial will examine the effects of combining several chemotherapy agents with an immunotherapy drug in children with solid tumors that have either recurred or do not show a significant response after initial treatment. Dr. Matthew Campbell, M.D., Assistant Professor of Pediatrics, member of the Harold C. Simmons Comprehensive Cancer Center and Pediatric Hematologist/Oncologist at Children’s Health, and his colleagues at UTSW will recruit six patients with solid tumors who failed initial treatment. Other hospitals participating in the trail include Dana-Farber Cancer Institute, Children’s Hospital of Philadelphia, Cincinnati Children’s Hospital Medical Center, Seattle Children’s Hospital, Lurie Children’s Hospital of Chicago, and Texas Children’s Hospital. The trial is set to be completed in January 2025.
Nanoscope Therapeutics, a clinical-stage biopharmaceutical company, announced positive results from their Phase 2b clinical trial, RESTORE. RESTORE utilizes MCO-010, an optogenetic therapy for vision restoration in advanced retinitis pigmentosa. Retinitis pigmentosa is a group of rare eye diseases that eventually leads to blindness for most patients. The company has also fully enrolled in a Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients. Stargardt Disease is a rare genetic eye disease that causes vision loss in children and in young adults. The MCO-010 therapy has received fast track and orphan drug designations from the FDA, allowing the company to get the much-needed treatment to patients quickly.
